Why the study?
Thrombopoietin can improve liver regeneration and fibrosis, leading authors to evaluate its use to improve liver function in liver cirrhosis.
Does human recombinant TPO improve liver function in a patient with liver cirrhosis?
Does human recombinant TPO improve liver function in a patient with liver cirrhosis?
Answers are grounded in this paper and cite their sources.
Recombinant human TPO may be effective for improving liver function and resolving ascites in patients with liver cirrhosis.
Thrombopoietin (TPO) can improve liver regeneration and fibrosis. We report on a patient with liver cirrhosis who received treatment with TPO to improve liver function. An 82-year-old male had liver cirrhosis with ascites due to hepatitis C virus infection. The Child–Pugh classification was Child B. The patient received human recombinant TPO for 12 months. The platelet counts increased and were maintained at 60–80×109/L. The liver function improved, the ascites resolved, and the liver volume increased. These results indicate that the novel treatment with recombinant human TPO (rhTPO) may be effective for improving liver function in patients with liver cirrhosis.
No takes yet. Share an insight, caveat, or question.
Xu et al. (2020) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: